Investigated for treating COVID-19.
- TRADE NAMES: Allerglobuline; Baygam; Beriglobulin; Citax; Endobulin; Gamafine; Gamastan; Gamimune (Bayer); Gamma 16; Gammabulin; Gammagard (Baxter); Gammar PIV (ZLB Behring); Gammer-IV; Gammonayiv; Gamunex (Bayer); IG Gamma; IGIM; Interglobin; IV Globulin-S; Iveegam (Baxter); Octagam; Panglobulin; Panzyga (Octapharma); Pentaglobin; Polygam S/D; Sandoglobulin; Sandoglobulina; Sandoglobuline; Venoglobulin (Alpha Therapeutics)
- INDICATIONS: Immunodeficiency in patients unable to produce sufficient amounts of IgG antibodies
- SYNONYM: IGIV; IVIG; Octagam; intravenous immunoglobulin (IVIg)
- CLASS: Covid-19 putative drug, Immunomodulator
- HALF-LIFE: N/A
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Live vaccines
- See adverse reactions attributed to class:
THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 03/04/2025
